J Bernard, M Weil, C Jacquillat. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » AdultAge FactorsAntineoplastic Agents/administration & dosageAntineoplastic Agents/adverse effectsBlood Cell CountBlood PlateletsBone Marrow ExaminationChildCytarabine/administration & dosageCytarabine/pharmacologyCytarabine/therapeutic useDaunorubicin/administration & dosageDaunorubicin/adverse effectsDaunorubicin/therapeutic useDoxorubicin/administration & dosageDoxorubicin/therapeutic useDrug Therapy, CombinationHeart/drug effectsHemorrhage/etiologyHumansHydrazones/therapeutic useInjections, IntravenousLeukemia, Monocytic, Acute/drug therapyLeukemia, Myeloid/drug therapyLeukemia, Myeloid, Acute/drug therapyLeukocyte Count
Substances： See more » Antineoplastic AgentsHydrazonesCytarabineDoxorubicinDaunorubicin
Year: 1974 PMID： 4596234 DOI： 10.1146/annurev.me.25.020174.000351
Source DB: PubMed Journal: Annu Rev Med ISSN： 0066-4219 Impact factor: 13.739